ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 140 filers reported holding ACCELERON PHARMA INC in Q1 2017. The put-call ratio across all filers is 2.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $356,717,000 | +1.4% | 2,072,735 | -26.1% | 0.03% | 0.0% |
Q2 2021 | $351,867,000 | -30.4% | 2,803,939 | -24.8% | 0.03% | -34.9% |
Q1 2021 | $505,374,000 | -15.6% | 3,726,672 | -20.3% | 0.04% | -18.9% |
Q4 2020 | $598,556,000 | -8.9% | 4,678,415 | -19.9% | 0.05% | -19.7% |
Q3 2020 | $657,273,000 | -10.1% | 5,840,860 | -23.9% | 0.07% | -17.5% |
Q2 2020 | $731,309,000 | +1.7% | 7,676,157 | -4.0% | 0.08% | -20.0% |
Q1 2020 | $718,965,000 | +70.3% | 8,000,072 | +0.5% | 0.10% | +112.8% |
Q4 2019 | $422,159,000 | +79.7% | 7,962,235 | +33.9% | 0.05% | +67.9% |
Q3 2019 | $234,988,000 | -11.3% | 5,947,556 | -7.7% | 0.03% | -9.7% |
Q2 2019 | $264,794,000 | -22.8% | 6,445,846 | -12.5% | 0.03% | -24.4% |
Q1 2019 | $342,939,000 | +13.7% | 7,363,953 | +6.3% | 0.04% | 0.0% |
Q4 2018 | $301,738,000 | -23.6% | 6,928,539 | +0.4% | 0.04% | -6.8% |
Q3 2018 | $394,909,000 | +84.7% | 6,900,369 | +56.6% | 0.04% | +76.0% |
Q2 2018 | $213,771,000 | +5.8% | 4,405,823 | -14.7% | 0.02% | +4.2% |
Q1 2018 | $202,045,000 | -6.8% | 5,167,390 | +1.2% | 0.02% | -4.0% |
Q4 2017 | $216,715,000 | +55.8% | 5,106,387 | +37.0% | 0.02% | +47.1% |
Q3 2017 | $139,080,000 | -3.3% | 3,726,674 | -21.2% | 0.02% | -5.6% |
Q2 2017 | $143,775,000 | +12.3% | 4,731,003 | -2.2% | 0.02% | +12.5% |
Q1 2017 | $128,064,000 | -4.2% | 4,838,087 | -7.7% | 0.02% | -11.1% |
Q4 2016 | $133,729,000 | -34.4% | 5,240,153 | -7.0% | 0.02% | -33.3% |
Q3 2016 | $203,937,000 | +7.8% | 5,635,185 | +1.2% | 0.03% | +3.8% |
Q2 2016 | $189,173,000 | +28.9% | 5,567,185 | +0.1% | 0.03% | +30.0% |
Q1 2016 | $146,733,000 | -39.7% | 5,560,161 | +11.5% | 0.02% | -39.4% |
Q4 2015 | $243,214,000 | +97.0% | 4,987,985 | +0.6% | 0.03% | +83.3% |
Q3 2015 | $123,476,000 | -20.7% | 4,958,861 | +0.8% | 0.02% | -10.0% |
Q2 2015 | $155,726,000 | -16.4% | 4,921,795 | +0.5% | 0.02% | -16.7% |
Q1 2015 | $186,366,000 | -1.1% | 4,896,648 | +1.2% | 0.02% | -4.0% |
Q4 2014 | $188,488,000 | +30.7% | 4,837,978 | +1.4% | 0.02% | +25.0% |
Q3 2014 | $144,232,000 | -10.0% | 4,769,562 | +1.1% | 0.02% | -4.8% |
Q2 2014 | $160,283,000 | +78.5% | 4,718,364 | +81.3% | 0.02% | +75.0% |
Q1 2014 | $89,796,000 | +25.7% | 2,602,777 | +44.3% | 0.01% | +20.0% |
Q4 2013 | $71,415,000 | – | 1,803,400 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Artal Group S.A. | 1,400,000 | $133,378,000 | 3.73% |
Foresite Capital Management III, LLC | 42,030 | $4,004,000 | 3.56% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 257,249 | $24,508,000 | 2.23% |
Cormorant Asset Management, LP | 600,000 | $57,162,000 | 2.18% |
Avoro Capital Advisors LLC | 1,040,000 | $99,081,000 | 1.96% |
QVT Financial LP | 101,396 | $9,660,000 | 1.64% |
FARALLON CAPITAL MANAGEMENT LLC | 2,100,000 | $200,067,000 | 1.60% |
Rhenman & Partners Asset Management AB | 155,000 | $14,767,000 | 1.60% |
Parkman Healthcare Partners LLC | 57,500 | $5,478,000 | 1.54% |
Ikarian Capital, LLC | 187,700 | $17,882,000 | 1.42% |